PuSH - Publication Server of Helmholtz Zentrum München

Odendahl, M.* ; Grigoleit, G.U.* ; Bönig, H.* ; Neuenhahn, M.* ; Albrecht, J. ; Anderl, F.* ; Germeroth, L.* ; Schmitz, M.* ; Bornhäuser, M.* ; Einsele, H.* ; Seifried, E.* ; Busch, D.H. ; Tonn, T.*

Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease.

Cytotherapy 16, 1245-1256 (2014)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
BACKGROUND AIMS: Reactivation of cytomegalovirus (CMV) after hematopoietic stem cell transplantation remains a major cause of morbidity despite improved antiviral drug therapies. Selective restoration of CMV immunity by adoptive transfer of CMV-specific T cells is the only alternative approach that has been shown to be effective and non-toxic. We describe the results of clinical-scale isolations of CMV-specific donor lymphocytes with the use of a major histocompatibility (MHC) class I peptide streptamer-based isolation method that yields minimally manipulated cytotoxic T cells of high purity. METHODS: Enrichment of CMV-specific cytotoxic T lymphocytes (CTLs) was performed by labeling 1 × 10(10) leukocytes from a non-mobilized mononuclear cell (MNC) apheresis with MHC class I streptamers and magnetic beads. Thereafter, positively labeled CMV-specific CTLs were isolated through the use of CliniMACS (magnetic-activated cell sorting), and MHC streptamers were released through the use of d-biotin. The purity of enriched CMV-specific CTLs was determined on the basis of MHC streptamer staining and fluorescence-activated cell sorting. RESULTS: A total of 22 processes were performed with the use of five different MHC class I streptamers. The median frequency of CMV-specific CTLs in the starting apheresis product was 0.41% among CD3+ T cells. The isolation process yielded a total of 7.77 × 10(6) CMV-specific CTLs, with a median purity of 90.2%. Selection reagents were effectively removed from the final cell product; the CMV-specific CTLs displayed excellent viability and cytotoxicity and were stable for at least 72 h at 4°C after MNC collection. CONCLUSIONS: Clinical-scale isolation of "minimally manipulated" CMV-specific donor CTLs through the use of MHC class I streptamers is feasible and yields functional CTLs at clinically relevant dosages.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Cmv-specific T Cells ; Clinimacs ; Mhc Streptamer Technology ; Adoptive T-cell Transfer; Stem-cell Transplantation; Allogeneic Bone-marrow; Cd8(+) T-cells; Hla-peptide Tetramers; Adoptive Transfer; Cmv Disease; Cytokine Secretion; Immunotherapy; Immunity; Reconstitution
ISSN (print) / ISBN 1465-3249
e-ISSN 1477-2566
Journal Cytotherapy
Quellenangaben Volume: 16, Issue: 9, Pages: 1245-1256 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place Oxford
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Molecular Immunology (IMI)
CCG Antigen-specific Immunotherapy (VIRO-KVA)